Acapsil – passive immunotherapy for wounds, ulcers and burns
Acapsil supports the immune system in its fight against infections in wounds, ulcers and burns. In clinic, it works 60% quicker than antibiotics and antiseptics; supports the wound healing processes; and provides 31% reduction of time in hospital.
Acapsil is developed and manufactured by the British company Willingsford Ltd.
Acapsil is patented globally.
Please visit the company website